Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2016) 5 OC1.1 | DOI: 10.1530/boneabs.5.OC1.1

ECTS2016 Oral Communications Clinical trials and osteoporosis treatment (6 abstracts)

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Kenneth G Saag 1 , Peter Alexandersen 2 , Claude-Laurent Benhamou 3 , Nigel Gilchrist 4 , Johan Halse 5 , E. Michael Lewiecki 6 , Kurt Lippuner 7 , Michael McClung 8 , Masataka Shiraki 9 , Carolyn A DaSilva 10 , Nadia Verbruggen 11 , Boyd B Scott 10 & Antonio Lombardi 10


1University of Alabama at Birmingham, Birmingham, Alabama, USA; 2Center for Clinical and Basic Research, Vejle, Denmark; 3Hôpital d’Orléans-la-Source, Orléans, France; 4The Princess Margaret Hospital, Christchurch, New Zealand; 5Osteoporoseklinikken, Oslo, Norway; 6New Mexico Clinical Research & Osteoporosis Center, Alburquerque, New Mexico, USA; 7Bern University Hospital, Bern, Switzerland; 8Oregon Osteoporosis Center, Portland, Oregon, USA; 9Research Institute and Practice for Involutional Diseases, Nagano, Japan; 10Merck & Co., Inc., Kenilworth, New Jersey, USA; 11MSD Europe Inc., Brussels, Belgium.

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.

Women aged ≥65 years, without baseline radiographic vertebral fracture (VFx) and total hip (TH) or femoral neck (FN) BMD T-score between −2.5 and −4.0, or with prior VFx and TH or FN T-score between −1.5 and −4.0, were randomised (1:1) to ODN 50 mg/week or placebo. All received vitamin D3 (5600 IU/week), and calcium as required. Treatment effects on primary endpoints (new and worsening morphometric vertebral, hip, and non-VFx) were investigated in subgroups (including by age, bisphosphonate intolerance, prior radiographic VFx, baseline BMD).

Of 16,713 randomised women (387 centres in 40 countries), 16,071 were analysed. Baseline mean age was 72.8 years, 57% Caucasian, 46% prior VFx. Mean BMD T-scores were: lumbar spine (LS) -2.7, TH -2.4, FN -2.7. The risk reduction of ODN versus placebo for primary fracture endpoints was generally consistent across all subgroups. For morphometric VFx, relative risk reductions (RRR) for participants with or without prior VFx were 51 and 60%, respectively; for age groups <70 and ≥70 years, RRRs were 57 and 53%, respectively; and, by baseline LS BMD T-score tertiles (≥−2.22; −3.25 to <−2.22; ≤−3.25), RRRs were 58, 47 and 54%, respectively. In bisphosphonate-intolerant patients, the RRR for morphometric VFx, hip and non-VFx were 52, 42 and 17%, respectively, consistent with the overall population. Post-hoc statistics revealed no significant interactions.

In postmenopausal women with osteoporosis, the effect of ODN vs placebo was generally consistent among predefined subgroups in reducing the risk of new and worsening morphometric vertebral, hip and non-VFx.

Volume 5

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

European Calcified Tissue Society 

Browse other volumes

Article tools

My recent searches

No recent searches.